Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

BACKGROUND: Most patients with ALK- or ROS1-rearranged non-small cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the central nervous system (CNS). This study aimed to determine the safety, efficacy, and pharmacoki...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, Alice T., Felip, Enriqueta, Bauer, Todd M., Besse, Benjamin, Navarro, Alejandro, Postel-Vinay, Sophie, Gainor, Justin F., Johnson, Melissa, Dietrich, Jorg, James, Leonard P., Clancy, Jill S., Chen, Joseph, Martini, Jean-François, Abbattista, Antonello, Solomon, Benjamin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777233/
https://www.ncbi.nlm.nih.gov/pubmed/29074098
http://dx.doi.org/10.1016/S1470-2045(17)30680-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777233/
https://www.ncbi.nlm.nih.gov/pubmed/29074098
http://dx.doi.org/10.1016/S1470-2045(17)30680-0

Ejemplares similares